Bristol-Myers Squibb Company [BMY] fell -8.21% so far this year. What now?



Bristol-Myers Squibb Company [NYSE: BMY] loss -2.43% or -1.42 points to close at $56.94 with a heavy trading volume of 13087924 shares. The company report on October 19, 2021 that SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, HNST, HYZN, SAM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits.

ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


The Boston Beer Company, Inc. (SAM)Class Period: 4/22/2021 – 9/8/2021 Lead Plaintiff Motion Deadline: November 15, 2021SECURITIES FRAUD To learn more, visit

It opened the trading session at $58.01, the shares rose to $58.15 and dropped to $56.92, the range by which the price of stock traded the whole day. The daily chart for BMY points out that the company has recorded -13.83% loss over the past six months. However, it is still -0.49% lower than its most recent low trading price.

If we look at the average trading volume of 9.38M shares, BMY reached to a volume of 13087924 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Bristol-Myers Squibb Company [BMY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $80.24 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Truist have made an estimate for Bristol-Myers Squibb Company shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 27, 2021. While these analysts kept the previous recommendation, Morgan Stanley dropped their target price from $70 to $62. The new note on the price target was released on April 30, 2021, representing the official price target for Bristol-Myers Squibb Company stock.

The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.13, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 2.82. The Price to Book ratio for the last quarter was 3.44, with the Price to Cash per share for the same quarter was set at 6.38. Price to Free Cash Flow for BMY in the course of the last twelve months was 16.81 with Quick ratio for the last quarter at 1.40.

Trading performance analysis for BMY stock

Bristol-Myers Squibb Company [BMY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.84. With this latest performance, BMY shares dropped by -7.13% in over the last four-week period, additionally sinking by -13.83% over the last 6 months – not to mention a drop of -7.02% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 29.74, with the RSI for the last a single of trading hit 30.98, and the three-weeks RSI is set at 30.21 for Bristol-Myers Squibb Company [BMY]. The present Moving Average for the last 50 days of trading for this stock 63.10, while it was recorded at 57.43 for the last single week of trading, and 64.08 for the last 200 days.

Bristol-Myers Squibb Company [BMY]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Bristol-Myers Squibb Company [BMY] shares currently have an operating margin of +10.56 and a Gross Margin at +51.04. Bristol-Myers Squibb Company’s Net Margin is presently recorded at -21.20.

Return on Total Capital for BMY is now 4.76, given the latest momentum, and Return on Invested Capital for the company is -9.87. Return on Equity for this stock declined to -20.16, with Return on Assets sitting at -7.26. When it comes to the capital structure of this company, Bristol-Myers Squibb Company [BMY] has a Total Debt to Total Equity ratio set at 136.62. Additionally, BMY Total Debt to Total Capital is recorded at 57.74, with Total Debt to Total Assets ending up at 43.61. Long-Term Debt to Equity for the company is recorded at 130.00, with the Long-Term Debt to Total Capital now at 54.94.

Reflecting on the efficiency of the workforce at the company, Bristol-Myers Squibb Company [BMY] managed to generate an average of -$298,017 per employee. Receivables Turnover for the company is 4.54 with a Total Asset Turnover recorded at a value of 0.34.Bristol-Myers Squibb Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.50.

Bristol-Myers Squibb Company [BMY]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Company go to 6.72%.

An analysis of insider ownership at Bristol-Myers Squibb Company [BMY]

There are presently around $93,192 million, or 75.40% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 197,341,430, which is approximately 0.344% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 175,100,707 shares of the stock with an approximate value of $9.97 billion in BMY stocks shares; and STATE STREET CORP, currently with $5.25 billion in BMY stock with ownership of nearly 1.316% of the company’s market capitalization.

>> 7 Top Picks for the Post-Pandemic Economy <<

Positions in Bristol-Myers Squibb Company stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 1,108 institutional holders increased their position in Bristol-Myers Squibb Company [NYSE:BMY] by around 85,353,768 shares. Additionally, 1,054 investors decreased positions by around 72,823,518 shares, while 307 investors held positions by with 1,478,499,249 shares. The mentioned changes placed institutional holdings at 1,636,676,535 shares, according to the latest SEC report filing. BMY stock had 140 new institutional investments in for a total of 13,224,950 shares, while 118 institutional investors sold positions of 5,692,819 shares during the same period.



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam